Compare Mesoblast Limited (MESO) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs TJX Companies Inc — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while TJX Companies Inc trades at $138.76 (market cap $152.62B). The key difference: TJX Companies Inc is far larger — about 87.2× Mesoblast Limited's market cap, and TJX Companies Inc pays a 1.38% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and TJX Companies Inc for 97 Days on average.
| MESO | TJX | |
|---|---|---|
Market Cap | $1.75B | $152.62B |
Volume | 239,027 | 8,079,794 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $168.41 |
52-Week Low | $13.19 | $122.84 |
Typical Hold Time | 15 Days | 97 Days |
Enterprise Value | $1.83B | $160.93B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
TJX trades at $138.75, down 0.04% on the day, with strong fundamental performance including 62.17% ROE and consistent earnings beats. The stock shows bullish technical momentum with support at $136 and resistance at $140. Revenue grew to $56.36B in 2025 with net income reaching $4.86B, while analyst consensus remains overwhelmingly positive with 85% buy ratings.
TJX presents a compelling investment case with projected 28% upside to the $174.15 consensus target, supported by expanding profit margins and robust cash flow generation. Key risks include competitive pressures in off-price retail and potential consumer spending volatility. The company's strong balance sheet and consistent dividend payments provide stability amid market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
